This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Firms Bringing New Treatments for Heart Disease

Several biotechnology firms announced progress today with new drugs aimed at helping patients suffering from heart failure.

Among the first new treatments in years, the new drugs are creating a buzz among the medical community that treats heart disease, one of the U.S.'s deadliest diseases and also one of its fastest-spreading, increasing about 10% per year.

Genentech (DNA), the South San Francisco, Calif.- biotech company, and Swiss biotech partner Actelion said today that their experimental intravenous drug Veletri (tezosentan) showed statistically significant improvements in blood circulation as well as in other heart measures, such as the amount of blood pumped by the heart.

The results came from an advanced study of 292 patients hospitalized for acute heart failure and were presented today at the American College of Cardiology conference in Orlando, Fla.

Genentech and Actelion are conducting additional trials for Veletri, with results expected later this year. The companies hope to receive Food and Drug Administration approval for the drug in 2002.

In a separate announcement, biotech firm Scios (SCIO) said Tuesday that its intravenous heart drug, Natrecor (nesiritide), improves blood circulation and alleviates symptoms associated with acute congestive heart failure.

In a study of 1,700 patients suffering from congestive heart failure, Natrecor was shown to rapidly improve blood circulation and alleviate shortness of breath and fatigue, the company said. The study was reviewed in this week's issue of the Journal of Cardiac Failure. The company added the study's result to its FDA application for approval of Natrecor.

If approved, Natrecor would be the first new treatment for acute congestive heart failure in more than a decade.

Five million Americans suffer from heart failure. There are about 1 million hospitalizations that cost the health care system $23 billion annually. Drugs like Natrecor, if approved, could help patients suffering from life-threatening heart failure, but also could reduce the cost of treatment.

John Sonnier, analyst with Prudential Vector Healthcare Group, expects ongoing trials of Natrecor to prove that the drug's use will reduce the length of hospital stays, which will reduce costs for patients and hospitals. That in turn will speed its adoption, he wrote in a research note. (Sonnier rates Scios a strong buy, and his firm has not done underwriting for Scios.)

In recent trading, Genentech was up 59 cents to $48.09. Scios was up 25 cents to $20.12.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs